Passage Bio, Inc.

Stage 4 · Declining · week 27

As of Oct 22, 2026, Passage Bio is in Stage 4, the downtrend phase, now in week 27 (since Apr 13, 2026). It closed at $3.51, 82.3% below its 52-week high and below its 200-day average, which is falling.

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. More about the company

$3.51

-2.23% today

$11.3M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PASG early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 18w

S2 15w

S4 20w

S4 18w

S2 15w

S4 28w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 18w → S1 6w → S2 15w → S3 10w → S4 20w → S1 9w → S4 18w → S1 7w → S4 8w → S1 7w → S2 15w → S3 5w → S4 28w current

Total tracked: 166 weeks across 13 stage runs.

PASG among Biotechnology394th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…394	PASGPassage Bio, Inc.	Stage 4 · wk 27	19	−29.8%

vs 52W High

-82.3%

$3.50 lo$19.85 hi

82.3% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 27

1w13w26w

Week 27, extended decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-47.3%

200 DMA: $6.67 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

2.05x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-29.8%

-28.9%

-40.5%

YTD

-70.0%

-59.9%

Scan Membership

Breakout Watch

Latest: 2024-02-02

2 appearances in last 60 days. First seen: 2020-12-16.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 27 · Vol 2.05x

2026-10-21S4

Wk 27 · Vol 0.10x

2026-10-20S4

Wk 27 · Vol 0.26x

2026-10-19S4

Wk 27 · Vol 0.50x

2026-10-16S4

Wk 27 · Vol 0.79x

2026-10-15S4

Wk 26 · Vol 0.75x

2026-10-14S4

Wk 26 · Vol 0.36x

2026-10-13S4

Wk 26 · Vol 0.65x

2026-10-12S4

Wk 26 · Vol 3.69x

2026-10-09S4

Wk 26 · Vol 0.60x

2026-10-08S4

Wk 25 · Vol 0.79x

2026-10-07S4

Wk 25 · Vol 0.70x

Moving averages & range

50 DMA

$4.41

200 DMA

$6.67

52W High

$19.85

52W Low

$3.50

5D Low

$3.50

Resistance levels (recent highs)

20d High

$4.80

60d High

$5.04

120d High

$6.12

250d High

$19.85

Next resistance

+36.8%

to 20d High

ROE

-169.1%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 2.5

Passage Bio: quick answers

What stage is Passage Bio in?

As of Oct 22, 2026, Passage Bio (PASG) is in Stage 4, the downtrend phase. It entered Stage 4 on Apr 13, 2026 and is in week 27. What the four stages mean

Is Passage Bio in an uptrend?

No. Passage Bio is in a Stage 4 downtrend. It trades 47.3% below its 200-day average, which is falling.

How far is Passage Bio from its 52-week high?

Passage Bio closed at $3.51 on Oct 22, 2026, 82.3% below its 52-week high of $19.85. Its 52-week low is $3.50.

How has Passage Bio performed over the past year?

As of Oct 22, 2026, Passage Bio is down 59.9% over the past year and down 70.0% so far in 2026.

Which sector and industry is Passage Bio in?

Passage Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.